Physician profile
Anil Kumar
NPI 1548209547
$7,961.36
in general payments reported to CMS, 2019-2025
46 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $583 · 2021: $1,294 · 2022: $1,456 · 2023: $1,123 · 2024: $1,190 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,779.96 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, Avista Mri |
| Abbvie INC. | $1,531.16 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,119.82 | 2019-2025 | Relistor |
| Redhill Biopharma INC. | $381.71 | 2020-2021 | |
| Fidia Pharma USA INC. | $291.89 | 2019-2024 | Triluron, Hymovis, Hyalgan |
| Teva Pharmaceuticals USA, INC. | $240.36 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $216.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $188.33 | 2022 | |
| Lundbeck LLC | $184.30 | 2024-2025 | Vyepti |
| Stimwave Technologies Incorporated | $147.49 | 2019-2020 | |
| Pfizer INC. | $143.44 | 2019-2025 | |
| Biodelivery Sciences International, INC. | $138.74 | 2019-2021 | |
| Abbott Laboratories | $116.05 | 2025 | Proclaim |
| Medtronic USA, INC. | $112.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $101.47 | 2019-2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $92.60 | 2022 | |
| Valinor Pharma, LLC | $88.18 | 2023-2024 | Movantik |
| Siemens Medical Solutions USA, INC. | $88.16 | 2020-2025 | Cios Flow, Cios Select |
| Scilex Pharmaceuticals INC. | $70.81 | 2019 | |
| Depuy Synthes Sales INC. | $66.38 | 2021-2024 | Monovisc, Orthovisc |
| Axsome Therapeutics, INC. | $65.64 | 2025 | Symbravo |
| Lilly USA, LLC | $62.90 | 2019 | |
| Zimmer Biomet Holdings, INC. | $60.88 | 2019 | |
| Globus Medical, INC. | $58.88 | 2025 | Senza |
| Spinal Simplicity, LLC | $50.55 | 2024 | Ha Minuteman G3-R |
| Nalu Medical, INC. | $46.60 | 2025 | Nalu Neurostimulation System |
| Amgen INC. | $46.08 | 2019-2021 | |
| Bioventus LLC | $44.96 | 2019-2024 | Supartz Fx Sodium Hyaluronate |
| Takeda Pharmaceuticals U.S.A., INC. | $44.23 | 2019-2020 | |
| Indivior INC. | $31.61 | 2024 | Sublocade |
| Kaleo, INC. | $30.87 | 2019 | |
| Avanos Medical | $30.00 | 2025 | Trivisc Sodium Hyaluronate |
| Vertex Pharmaceuticals Incorporated | $29.81 | 2025 | |
| Alnylam Pharmaceuticals INC. | $28.57 | 2024 | Onpattro |
| Biotronik Nro, INC. | $26.20 | 2025 | Prospera |
| Alkermes, INC. | $24.16 | 2019 | |
| Antares Pharma, INC. | $23.70 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.40 | 2021 | |
| Novo Nordisk INC | $19.53 | 2023 | Wegovy |
| Neuronetics, INC. | $18.98 | 2021 | |
| Medtronic, INC. | $17.54 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $17.43 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.42 | 2019 | |
| Nevro Corp. | $14.82 | 2020 | |
| Shionogi INC | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,666.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.